The Valley Desk

NCT03861793 · Interventional trial

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Overall registry status Completed

Phase 1 · Phase 2

Conditions Advanced Solid Tumors

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov